204 related articles for article (PubMed ID: 26549431)
1. Histone Modifications as Molecular Targets in Nasopharyngeal Cancer.
Shyamasundar S; Dheen ST; Bay BH
Curr Med Chem; 2016; 23(2):186-97. PubMed ID: 26549431
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
3. EBV Infection and Glucose Metabolism in Nasopharyngeal Carcinoma.
Zhang J; Jia L; Tsang CM; Tsao SW
Adv Exp Med Biol; 2017; 1018():75-90. PubMed ID: 29052133
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
5. Regulation of DNA Damage Signaling and Cell Death Responses by Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) and LMP2A in Nasopharyngeal Carcinoma Cells.
Wasil LR; Wei L; Chang C; Lan L; Shair KH
J Virol; 2015 Aug; 89(15):7612-24. PubMed ID: 25972552
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
Ganai SA
Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin.
Perri F; Della Vittoria Scarpati G; Giuliano M; D'Aniello C; Gnoni A; Cavaliere C; Licchetta A; Pisconti S
Anticancer Drugs; 2015 Nov; 26(10):1017-25. PubMed ID: 26241803
[TBL] [Abstract][Full Text] [Related]
9. Targeting the crosstalk of epigenetic modifications and immune evasion in nasopharyngeal cancer.
Looi CK; Foong LC; Chung FF; Khoo AS; Loo EM; Leong CO; Mai CW
Cell Biol Toxicol; 2023 Dec; 39(6):2501-2526. PubMed ID: 37755585
[TBL] [Abstract][Full Text] [Related]
10. EBV-miR-BART10-3p facilitates epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma by targeting BTRC.
Yan Q; Zeng Z; Gong Z; Zhang W; Li X; He B; Song Y; Li Q; Zeng Y; Liao Q; Chen P; Shi L; Fan S; Xiang B; Ma J; Zhou M; Li X; Yang J; Xiong W; Li G
Oncotarget; 2015 Dec; 6(39):41766-82. PubMed ID: 26497204
[TBL] [Abstract][Full Text] [Related]
11. Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens.
Tu C; Zeng Z; Qi P; Li X; Yu Z; Guo C; Xiong F; Xiang B; Zhou M; Gong Z; Liao Q; Yu J; He Y; Zhang W; Li X; Li Y; Li G; Xiong W
J Virol; 2017 Sep; 91(17):. PubMed ID: 28637758
[TBL] [Abstract][Full Text] [Related]
12. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
13. Identification of Novel Small Organic Compounds with Diverse Structures for the Induction of Epstein-Barr Virus (EBV) Lytic Cycle in EBV-Positive Epithelial Malignancies.
Choi CK; Ho DN; Hui KF; Kao RY; Chiang AK
PLoS One; 2015; 10(12):e0145994. PubMed ID: 26717578
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of DNA methylation in Epstein-Barr virus-associated nasopharyngeal carcinoma by bisulfite amplicon sequencing.
Zhao W; Mo Y; Wang S; Midorikawa K; Ma N; Hiraku Y; Oikawa S; Huang G; Zhang Z; Murata M; Takeuchi K
BMC Cancer; 2017 Jul; 17(1):489. PubMed ID: 28716111
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of histone deacetylases induces formation of multipolar spindles and subsequent p53-dependent apoptosis in nasopharyngeal carcinoma cells.
Yan M; Qian YM; Yue CF; Wang ZF; Wang BC; Zhang W; Zheng FM; Liu Q
Oncotarget; 2016 Jul; 7(28):44171-44184. PubMed ID: 27283770
[TBL] [Abstract][Full Text] [Related]
16. The periodontal pathogen Porphyromonas gingivalis induces the Epstein-Barr virus lytic switch transactivator ZEBRA by histone modification.
Imai K; Inoue H; Tamura M; Cueno ME; Inoue H; Takeichi O; Kusama K; Saito I; Ochiai K
Biochimie; 2012 Mar; 94(3):839-46. PubMed ID: 22178321
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
[TBL] [Abstract][Full Text] [Related]
18. Switching of EBV cycles between latent and lytic states.
Murata T; Tsurumi T
Rev Med Virol; 2014 May; 24(3):142-53. PubMed ID: 24339346
[TBL] [Abstract][Full Text] [Related]
19. EBV encoded miR-BHRF1-1 potentiates viral lytic replication by downregulating host p53 in nasopharyngeal carcinoma.
Li Z; Chen X; Li L; Liu S; Yang L; Ma X; Tang M; Bode AM; Dong Z; Sun L; Cao Y
Int J Biochem Cell Biol; 2012 Feb; 44(2):275-9. PubMed ID: 22108199
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors.
Krishna S; Kumar V; Siddiqi MI
Curr Top Med Chem; 2016; 16(9):934-47. PubMed ID: 26303428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
